Subsequent Primary Cancer Diagnoses Among Patients With Neuroendocrine Tumors - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Risk of Subsequent Primary Cancers in Patients Diagnosed With Neuroendocrine Tumors

  • By

  • Manas Pustake

  • Charles W. Shi

  • Matthew T. Gao

  • Nicholas J. Hornstein

  • Seth J. Concors

  • Timothy J. Brown

  • Udhayvir S. Grewal

  • November 16, 2026

Share

Objective:

To assess how age at neuroendocrine tumor (NET) diagnosis is associated with subsequent primary cancer (SPC) occurrence.

Approach:
  • Design and data: Cohort study using SEER data for patients diagnosed with NETs from 2000 through 2021.
  • Exposure and outcome: Compared early-onset NET (diagnosis before age 50) with average-onset NET (age 50 or older). The outcome was the first malignant SPC diagnosed in a subsequent calendar year.
  • Analysis: Used adjusted Fine-Gray competing-risk models, treating death before SPC as a competing event. Because proportionality was violated, age-group associations were estimated at selected follow-up times.
Key Findings:
  • Among 95,625 patients, 7,086 (7.41%) developed an SPC during a median 47-month follow-up.
  • SPCs occurred in 4.97% of patients with early-onset NETs and 8.06% of those with average-onset NETs.
  • Compared with average-onset NET, early-onset NET was associated with lower adjusted SPC subdistribution hazards at 1 year (sHR 0.35; 95% CI, 0.30–0.41), 3 years (0.50; 0.46–0.54), 5 years (0.59; 0.55–0.63), and 10 years (0.73; 0.67–0.80).
  • Among patients with early-onset NET, gastric, pancreatic, and small-intestinal primary sites were associated with higher SPC risk; appendiceal NETs were associated with lower risk.
Interpretation:

Early-onset NET was associated with lower overall SPC hazards, with the association attenuating over longer follow-up. The authors describe the findings as observational and note that they do not support changing population-based cancer screening recommendations.

Limitations:
  • Follow-up was relatively short.
  • Observational registry data may have residual confounding.
  • Hereditary and sporadic NETs could not be reliably distinguished, and detailed treatment-exposure information was unavailable.
  • The study did not compare cancer incidence with expected incidence in the general population.
Conclusion:

SPC risk varied by age and disease characteristics among patients with NETs; the authors suggest survivorship strategies account for demographic and disease-specific features.

Sources:

Original Source(s)

Related Content